Townsend Letter Alternative Medicine Magazine



  FREE e-Edition


 EDTA Chelation Therapy


 E-mail List

From the Townsend Letter
August / September 2013

Fever Therapy in Oncology
by Gurdev Parmar, ND, FABNO
Search this site

Page 1, 2

1.      Nesse RM, Williams GC. Why We Get Sick: The New Science of Darwinian Medicine. New York: Vintage Books; 1994.
2.      Kluger MJ. Fever: Basic Measurement and Management. New York: Raven Press; 1990.
3.      Hildebrandt, B, Hegewisch-Becker S, et al. Current status of radiant whole-body hyperthermia at temperatures >41.5 C and practical guidelines for the treatment of adults. The German ‘Interdisciplinary Working Group on Hyperthermia.'; Int J Hyperthermia. March 2005;21(2):169–183.
4.      Levin EJ. Spontaneous regression of a malignant tumor of bone. Cancer. 1957;10:377–381.
5.      Cole WH. Spontaneous regression of reticulum-cell sarcoma of bone. J Bone Joint Surg. 1959;41-A:960–965.
6.      Callan JE, Wood VE, Linda L. Spontaneous resolution of an osteocbondroma. J Bone Joint Surg (Am). 1975;57(5):723.
7.      Copeland RL, Meehan PL, Morrissy RT. Spontaneous regression of osteochondromas. Two case reports. J Bono joint Surg (Am). 1985;67(6)971–973.
8.      Eisenbud L, Kahn LB, Friedman E. Benign osteoblastoma of the mandible: Fifteen year follow-up showing spontaneous regression after biopsy. J Oral Maxillofac Surg.1987;45(1):53–57.
9.      Margolis J, West D. Spontaneous regression of malignant disease: Report of three cases. J Am Geriatr Soc. 1967;15(3):251–253.
10.    Rao S, Constantini S, Gomori JM, et al. Spontaneous involution of an intra-axial brain stem lesion: A case report. Pediatr Neurosurg. 1995;23(5):279–281.
11.    Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;2(715):105–106.
12.    Rebollo J, Llorente I, Yoldi A. Spontaneous tumor regression in a patient with metastatic gastric cancer. Communication of an additional case. Rev Med Univ Navarra. 1990;34(3):141–142.
13.    Garcia JL, Torres Serrano F, Lopez Rubio F, et al. Spontaneous tumor regression and gastric cancer (letter). An Med Interna. 1996;13(1):47–48.
14.    Woods JE. The influence of immunologic responsiveness on head and neck cancer. Therapeutic implications. Plast Reconstr Surg. 1975;56(1):77–80.
15.    Chien RN, Chen TJ, Liaw YF. Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol. 1992;87(7):903–905.
16.    Hart S. Chronic lymphatic leukemia complicated by pneumonia. New York State J Med. 1903;78;220–227.
17.    Bassen FA, Kohn JL. Multiple spontaneous remissions in a child with acute leukemia. The occurrence of agranulocytosis and aplastic anemia in acute leukemia and their relationship to Remissions. Blood. 1952;7:37–46.
18.    Wiernik PH. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976;44;35–38.
19.    Barton JC, Conrad ME. Beneficial effect of hepatitis in patients with acute myelogenous leukemia. Ann Int Med. 1979;90;188–190.
20.    Conrad ME, Barton JC. Hepatitis and leukemia (letter). Ann Int Med. 1979;90:988.
21.    Foon KA, Yale C, Clodfelter K, et al. Post-transfusion hepatitis in acute myelogenous leukemia: Effect on survival. JAMA. 1980;244;1806–1807.
22.    Delmer A, Heron E, Marie JP, et al. Spontaneous remission in acute myeloid leukaemia (Letter; comment). Br J Haematol. 1994;87(4):880–882.
23.    Musto P, D';Arena G, Melillo L, et al. Spontaneous remission in acute myeloid leukaemia: A role for endogenous production of tumour necrosis factor and interleukin-2 (Letter; comment). Br J Haematol. 1994;87(4);879–880.
24.    Lefrere F, Hermine O, Radford-Weiss I, et al. A spontaneous remission of lymphoid blast crisis in chronic myelogenous leukaemia following blood transfusion and infection. Br J Haematol. 1994;88(3);621–622.
25.    Greentree LB. Anaplastic lung cancer with metastases. Case report of a 15 year survival. Ohio State Med. 1973;69(11);841–843.
26.    Marcos Sanchez F, Juarez Ucelay F, Bru Espino IM, et al. A new case of spontaneous tumor regression (letter). An Med Interna. 1991;8(9):468.
27.    Zygiert Z. Hodgkin's disease; remissions after measles. Lancet.1971;1:593.
28.    Ziegler JL. Spontaneous remission in Burkitt's lymphoma. Nat Cancer Monogr. 1976;44:61–65.
29.    Gattiker HH, Wiltshaw E. Galton DA. Spontaneous regression in non-Hodgkin's lymphoma. Cancer. 1980;May 15;45(10);2627–2632.
30.    McQain K. Warkentin P, Kay N. Spontaneous remission of Burkitt's lymphoma associated with herpes zoster infection. Am J Pediatr Hematol Oncol. Spring 1995;7(1):9–14.
31.    Kempin S, Cirrincione C, Straus DS, et al. Improved remission rate and duration in nodular non-Hodgkin lymphoma (NNHL) with the use of mixed bacterial vaccine (MBV). Proc Am Soc Clin Oncol. 1981;22:514.
32.    Kempin S, Cirrincione C, Myers J, et al. Combined modality therapy of advanced nodular lymphoma (NL) – The role of nonspecific immunotherapy (MBV) as an important determinant of response and survival. Proc Am Soc Clin Oncol. 1983;24:56.
33.    Grem JL, Hafez GR, Brandenburg JH, et al. Spontaneous remission in diffuse large cell lymphoma. Cancer. 1986;57(10);2042–2044.
34.    Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations. Am J Hemacol. 1989;31(2):138–141.
35.    Wolf JW. Prolonged spontaneous remission of case of malignant lymphoma. Mo Med. 1989;86(5);275–277.
36.    Sureda M, Subira ML, Marcin Algarra S, et al. Spontaneous tumor regression. Report of 2 cases. Mod Clin (Bare). 1990;95(8);306–308.
37.    De Berker D, Windebank K, Sviland L, et al. Spontaneous regression in angiocentric T-cell lymphoma. Br J Dermatol. 1996;134(3):554–558.
38.    Bagshawe KD. Tumor growth and anti-mitotic action. The role of spontaneous cell losses. Br J Cancer. 1968;22;698–713.
39.    Muckle DS, Dickson JA, Johnston ID. High fever and cancer. Lancet. 1971;8:972.
40.    Schwartz DB, Zbar B, Gibson WF, et al. Inhibition of murine sarcoma virus oncogenesis with living BCG. Int J Cancer. 1971;8:320–325.
41.    Cho-Chung YS, Gullino PM. Mammary tumor regression. V. Role of acid ribonuclease and cathepsin. J Biol Chem. 1973 Jul 10;248(13):4734–4739.
42.    Cho-Chung YS, Gulino PM. Mammary tumor regression. VI. Synthesis and degradation of acid ribonuclease. J Biol Chem. 1973b;248(13);4750–4755.
43.    Ibid.
44.    Berendt MJ. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell mediated immunity. J Exp Med.1978a;148:1550–1559.
45.    Berendt MJ. The immunological basis of endotoxin-induced tumor regression. Requirement for a preexisting state of concomitant anti-tumor immunity. J Exp Med. 1978b;148:1560–1569.
46.    Pedersen NC, Johnson L, Theilen GH. Biological behavior of tumors and associated retroviremia in cats inoculated with Snyder-Theilen fibrosarcoma virus and the phenomenon of tumor recurrence after primary regression. Infect Immun. 1984;43(2):631–636.
47.    Bolande RP. Spontaneous regression and cytodifferentiation of cancer in early life: The oncogenic grace period. Surv Synth Pathol Res. 1985;4(4);296–311.
48.    Baker HW. Biologic control of cancer. The James Ewing lecture. Arch Surg. 1986;121(11):1237–1241.
49.    Stone OJ. Acute local inflammation causing generalized increased ground substance viscosity: Guttate psoriasis, Reiter's syndrome, adjuvant disease, cancer regression. Med Hypotheses. 1988;25(3);141–145.
50.    Jarpe MA, Hayes MP, Russell JK, et al. Causal association of interferon-gamma with tumor regression. J Interferon Res. 1989;9:239–244.
51.    Seacrist L. Spontaneous cancer remissions spark questions (news). J Natl Cancer Inst. 1993;85(23);1892–1895.
52.    Halliday GM, Patel A, Hunt MJ, et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. World J Surg. 1995;19(3):352–358.
53.    Gunale S, Tucker WG. Regression of metastatic melanoma. Mich Med. 1975;74:697–698.
54.    Cook MG. The significance of inflammation and regression in melanoma [editorial]. Virchows Arch A Pathol Anat Histopathol. 1992;420(2):113–115.
55.    Grafton WO. Regressing malignant melanoma. J La State Med Soc. 1994;146(12):535–539.
56.    Motofei IG. Herpetic viruses and spontaneous recovery in melanoma. Med Hypotheses. 1996;47(2):85–88.
57.    London RE. Multiple Myeloma: Report of a case showing unusual remission lasting two years following severe hepatitis. Ann Int Med. 1955;43:191–201.
58.    Schurmans JR. Blijenberg BG, Mickisch GH, et al. Spontaneous remission of a bony metastasis in prostatic adenocarcinoma. J Urol. 1996;155(2):653.
59.    Katz SE, Schapira HE. Spontaneous regression of genitourinary cancer – an update. J Urol. 1982;128:1–4.
60.    Mangiapan G, Guigay J, Milleron B. A new case of spontaneous regression of metastasis of kidney cancer (letter). Rev Pneumol Clin. 1994;50(3):139–140.
61.    Edwards MJ, Anderson JA, Angel JR, et al. Spontaneous regression of primary and metastatic renal cell carcinoma. J Urol. 1996;155(4):1385.
62.    Hunter WS. Unexpected regressed retinoblastoma. Can J Ophthalmol. 1968;3(4):376–801.
63.    Verhoeff FH. Retinoblastoma undergoing spontaneous regression. Calcifying agent suggested in treatment of retinoblastoma. Am J Ophthalmol. 1966;62(3):573–574.
64.    Jain IS, Singh K. Retinoblastoma in phthisis bulbi. J All India Ophthalmol Soc. 1968;16(2):76–78.
65.    Dobson L, Dickey LB. Spontaneous regression of malignant tumors. Am J Surg. 1956;92:162–173.
66.    Sindelar WF. Regression of cancer following surgery. Natl Cancer Inst Monogr. 1976;44:81–84.
67.    Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545–550.
68.    Watson AL. A case of recurrent sarcoma with apparently spontaneous cure and gradual shrinking of the tumour. Lancet. 1902;1:300–301.
69.    Shore BR. Spontaneous cure of congenital recurring connective tissue tumor. Am J Cancer. 1936;27,736–739.
70.    Penner OW. Spontaneous regression of a case of myosarcoma. Cancer. 1953;6:776–779.
71.    Berner RE, Laub DL. The spontaneous cure of massive fibrosarcoma. Plastic Reconstructive Surg. 1965;36,257–262.
72.    Weintraub LR. Lymphosarcoma. Remission associated with viral hepatitis. JAMA. 1969;210,1590–1591.
73.    Lei KI, Gwi E, Ma L, et al. Spontaneous regression of advanced leiomyosarcoma of the urinary bladder. Oncology. 1997;54(1):19–22.
74.    Cole WH. Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr. 1976 Nov;44:5–9.
75.    Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17(3):201–209.
76.    Dock G. The influence of complicating diseases upon leukemia. Am J Med Sci. April 1904;127(4):563–592.
77.    Kizaki M, Ogawa T, Watanabe Y, et al. Spontaneous remission in hypoplastic acute leukemia. J Med. 1988;37(3);299–307.
78.    Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1970;59(5):642–644.
79.    Ruckdeschel JC, Codish SD, Stranahan A, et al. Postoperative empyema improves survival of cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972;287(20).
80.    Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;2(715):105–106.
81.    Rohdenburg GL. Fluctuations in the growth energy of malignant tumors in man, with especial reference to spontaneous regression. J Cancer Res. 1918;3:193–225.
82.    Everson TC, Cole WH. Spontaneous regression of cancer: Preliminary report. Ann Surgery. 1956;144:366–383.
83.    Everson TC. Spontaneous regression of cancer. Ann New York Acad Sci. 1964;114:721–735.
84.    Everson TC. Spontaneous regression of cancer. Prog Clin Cancer. 1967;3:79–91.
85.    Everson TC, Cole WH. Spontaneous regression of cancer. A study and abstract of world medical literature and personal communications concerning spontaneous regression of malignant disease. Philadelphia, London: WB Saunders Co.; 1966.
86.    Maurer S, Kolmel K. Spontaneous Regression of Melanoma. New York: Cancer Research Inst Inc.; 1997.
87.    Nauts HC. The beneficial effects of bacterial infections on host resistance to cancer. End results in 449 cases. A study and abstracts of response in the world medical literature (1775–1980) and personal communications. New York: Cancer Research Institute Inc.; 1980. 1032 references. Monograph 8. 2nd ed.
88.    Laurence JZ. The diagnosis of surgical cancer (Liston Prize Essay for 1854). London: John Churchill.
89.    Schmidt KL. Krebs und Infekcionskrankheiten. Med Klinik Wschr. 1910;43:1690–1693.
90.    Engel P. Ober den Infektionsindex dee Krebskranken. Wien Klin Wschr. 1934;47:1.
91.    Engel P. Ober den Einfluß des Alters auf den Infektionsindex der Krebskranken. Wien Klin Wschr. 935;48;ll2.
92.    Newhouse ML, Pearson RM, Fullerton JM, et al. A case control study of carcinoma. Brit J Preventive Social Med. 1977;31:148–153.
93.    Ronne T. Measles virus infection without rash in children is related to disease in adults. Lancet. 1985;8419i:1–5.
94.    Nauts HC. Bacterial vaccine therapy of cancer. Dev Biol Stand. 1977;38:487–494.
95.    Nauts HC. Bacterial products in the treatment of cancer: past, present and future. Paper presented at: International Colloquium on Bacteriology and Cancer. l982a.
96.    Nauts HC. Bacterial pyrogens: Beneficial effects on cancer patients. Prog Clin Biol Res. 1982b;07;687–696.
97.    Nauts HC. Breast Cancer: Immunological, Factors Affecting Incidence, Prognosis and Survival. New York: Cancer Research Institute Inc.; 1984:261.
98.    Nauts HC. Bacteria and cancer-antagonisms and benefits. Cancer Surv. 1989;8:713–723.
99.    Nauts HC. Beneficial Effects of Immunotherapy (Bacterial Toxins) on Sarcoma of the Soft Tissues, Other Than Lymphosarcoma. New York: Cancer Research Institute Inc.; 1975.
100.  Nauts HC. Bibliography of reports concerning the clinical or experimental use of Coley Toxins (Streptococcus pyogenes and Serratia marcescens), 1893–1984. New York: Cancer Research Institute Inc.; 1997.
101.  Nauts HC. Ewing's Sarcoma of Bone: End Results Following Immunotherapy (Bacterial Toxins) Combined with Surgery and/or Radiation. New York: Cancer Research Institute Inc.; 1974.
102.  Nauts HC. Giant Cell Tumor of Bone: End Results Following Immunotherapy (Coley Toxins) Alone or Combined with Surgery and/or Radiation – 66 Cases and Concurrent Infection – 4 Cases. New York: Cancer Research Institute Inc.; 1976.
103.  Nauts HC. Osteogenic Sarcoma: End Results Following Immunotherapy with Bacterial Vaccines: 65 Cases Following Bacterial Infections, Inflammation or Fever, 41 Cases. New York: Cancer Research Institute Inc.; 1974.
104.  Nauts HC. The Beneficial Effects of Bacterial Infections on Host Resistance to Cancer. End Results in 449 Cases. A Study and Abstracts of Response in the World Medical Literature (1775–1980) and Personal Communications. New York: Cancer Research Institute Inc.; 1980;(1032 references). Monograph No. 8. 2nd ed.
105.  Nauts HC, Fowler GA. End Results in Lymphosarcoma Treated by Toxin Therapy Alone or Combined with Surgery and/or Radiation or with Concurrent Bacterial Infection. New York Cancer Research Institute Inc.; 1969. Monograph No. 6.
106.  Nauts HC, McLaren JR. Coley toxins – the first century. Adv Exp Med Biol. 1990;267:483–500.
107.  Nauts HC, Swift WE, Coley LB. Treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946;6:205–216.
108.  Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's Toxins) on malignant tumors in man. Acta Med Scand. 1953;146(suppl 276):1–103. (New York: Cancer Research Institute Inc.; 1953. Monograph No. 1).
109.  Nauts HC. Beneficial Effects of Acute Concurrent Infection, Inflammation, Fever or Immunotherapy (Bacterial Toxins) on Ovarian and Uterine Cancer. New York Cancer Research Institute Inc.; 1977. Monograph No. 17.
110.  Nauts HC. Enhancement of Natural Resistance to Renal Cancer: Beneficial Effects of Concurrent infections and Immunotherapy with Bacterial Vaccines. New York: Cancer Research Institute Inc.;1970. Monograph No. 12.
111.  Issels J. Immunotherapy in progressive metastatic cancer. Clin Trials J. 1970;3:357–366.
112.  Ardenne M von. Spontaneous remission of tumors following hyperthermia – a feedback process. Naturwissenschaften. 1965;52(23):645.
113.  Sakaguchi Y, Makino M, Kaneko T, et al. Therapeutic efficacy of long duration–low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats. Cancer Res. 1994;54:2223–2227.
114.  Ohno S, Strebel FR, Stephens LC, et al. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer. 1993;68:469–474.
115.  Strebel FR, Proett JM, Rowe RW, Deng W, Bull JMC. Effect of oxaliplatin combined with fever-range whole body thermal-therapy in a rat mammary adenocarcinoma in vivo. Proc Am Assoc Cancer Res. 2006;47:905 [abstract 3847].
116.  Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res. 1989;49:7041–7044.
117.  Katschinski DM, Wiedemann GJ, Mentzel M, Mulkerin DL, Touhidi R, Robins HI. Optimization of chemotherapy administration for clinical 41.8C whole body hyperthermia. Cancer Lett. 1997;115:195–199.
118.  Bull JMC, Loo CH, Strebel FR, Jenkins GN, Tomoda M, Rowe, RW. Treatment of a highly metastatic mammary adenocarcinoma with fever-range, long-duration, low-temperature (40C for 6h) whole body hyperthermia (LL-WBH) combined with gemcitabine (dFdC) in rats. Proc Am Assoc Cancer Res. 1999;40:552 [abstract 3643].
119.  Matsuda H, Strebel FR, Kaneko T, et al. Long duration-mild whole body hyperthermia of up to 12 hours in rats: Feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: Implications for adjuvant therapy. Int J Hyperthermia. 1997;13:89–98.
120.  Toyota N, Strebel FR, Stephens LC, Matsuda H, Bull JM. Long-duration, mild whole body hyperthermia with cisplatin: Tumour response and kinetics of apoptosis and necrosis in a metastatic rat mammary adenocarcinoma. Int J Hyperthermia. 1997;13:497–506.
121.  Richel O, Zum Vörde Sive Vörding PJ, Rietbroek R, et al Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecol Oncol. 2004;95:680–685.
122.  Ohno S, Siddik ZH, Baba H, et al. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res. 1991;51:2994–3000.
123.  Wondergem J, Stephens LC, Strebel FR, et al. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues. Cancer Res. 1991;51:3559–3567.
124.  Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463.
125.  Vertrees RA, Das GC, Popov VL, et al. Synergistic interaction of hyperthermia and gemcitabine in lung cancer. Cancer Biol Ther. 2005;4:1144–1153.
126.  Saper CB, Breder CD. The neurologic basis of fever. New Engl J Med. 1994;30:1880–1886.
127.  Ding XZ, Fernandez-Prada, CM, Bhattacharjee AK, Hoover DL. (2001). Over-expression of hsp-70 inhibits bacterial lipopolysaccharide-induced production of cytokines in human monocyte-derived macrophages. Cytokine. 16:210–219.
128.  Ensor JE, Crawford EK, Hasday JD. Warming macrophages to febrile range destabilizes tumor necrosis factor-alpha mRNA without inducing heat shock. Am J Physiol. 1995;269:C1140–C1146.
129.  Ensor JE, Wiener SM, McCrea KA, Viscardi RM, Crawford EK, Hasday JD. Differential effects of hyperthermia on macrophage interleukin-6 and tumor necrosis factor-alpha expression. Am J Physiol. 1994;266:C967–C974.
130.  Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:281–286.
131.  Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis. 1999;179(suppl 2):s294–s304.
132.  Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem. 1975;44:669695.
133.  Kappel M, Stadeager C, Tvede N, et al. Effects of in vivo hyperthermia on natural killer cell activity, in vitro proliferative responses and blood mononuclear cell subpopulations. Clin Exp Immunol. 1991;84: 175–180.
134.  Wallin RPA, Lundqvist A, Moré SH, et al. Heat shock proteins as activators of the innate immune system. Trends Immunol. 2002;23:130–135.
135.  Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance and their relevance to clinical hyperthermia. Int J Hyperthermia. 1995;11:459–488.
136.  Baronzio GF, Hager ED. Hyperthermia in Cancer Treatment: A Primer. Medical Intelligence Unit. Springer Science and Business Media. Texas, US; 2006.